Science 37 Appoints SVP, Erica Prowisor, to Bolster Patient Recruitment Velocity, Diversity
April 25 2023 - 7:59AM
Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading
Metasite™, announced today Erica Prowisor as SVP of Patient and
Provider Networks to accelerate patient recruitment, ensure
participant diversity and gain operational efficiencies.
Erica has been forging new ground as a leader in patient
recruitment for nearly 20 years, most notably with IQVIA where she
was Global Head of Recruitment and Retention for more than three
years and led the company’s direct-to-patient recruitment and
retention efforts. Prior to IQVIA, Erica spent 11 years with
Acurian through the acquisition by PPD where she was Head of
Enrollment Operations, and in charge of global operations for the
company’s Accelerated Enrollment Solutions business.
“As a Metasite, we access patients that can’t be accessed by
traditional brick and mortar sites, and we have proven to enroll
patients significantly faster on almost every single trial,” said
Darcy Forman, Chief Delivery Officer at Science 37. “With Erica’s
prolific experience in patient recruitment, we are excited to
further accelerate our recruitment velocity and extend our
leadership position, while also gaining efficiencies that can lower
our cost per acquisition.”
"The Science 37 Metasite™ offers a unique opportunity to
transform clinical trials by providing expansive access,” said
Erica Prowisor. “I look forward to being able to help drive better
patient outcomes by finding the most representative patient
populations, regardless of location."
Science 37 boasts myriad channels for recruiting patients
including its own network of more than 600 thousand patients,
approximately 35 thousand community providers that reach
approximately 35 million patient lives, in addition to partnerships
with third-party patient communities, pharmacies, labs,
associations, and digital media outlets. The company uses an
omnichannel approach to find patients, and a high-efficiency
enrollment process that includes an online screening process, a
technology-enabled contact center, and eConsent to ensure that no
patient is left behind.
About Science 37Science 37 Holdings, Inc.’s
(Nasdaq: SNCE) mission is to accelerate clinical research by
enabling universal trial access for patients. Through our Metasite™
we reach an expanded population beyond the traditional site,
delivering on our goal of clinical research that works for
everyone—with greater patient diversity. Patients gain the
flexibility to participate from the comfort of their own homes, at
their local community provider, or at a traditional site when
needed. Our Metasite is powered by a proprietary technology
platform with in-house medical and operational experts that drive
uniform study orchestration, enabling greater compliance and
high-quality data. To learn more, visit www.science37.com, or email
science37@science37.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains certain forward-looking statements
within the meaning of the federal securities laws, including
statements regarding the products offered by Science 37 and the
markets in which it operates, and Science 37’s anticipated growth
and profitability. These forward-looking statements generally are
identified by the words “believe,” “can,” “could”, “seek”,
“project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “might”,
“should,” “will,” “would,” “will be,” “will continue,” “will likely
result” and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this press release, including but not
limited to: (i) the ability to maintain the listing of Science 37’s
securities on The Nasdaq Stock Market LLC, (ii) volatility in the
price of Science 37’s securities due to a variety of factors,
including changes in the competitive and highly regulated
industries in which Science 37 operates, variations in performance
across competitors, changes in laws and regulations affecting
Science 37’s business, changes in its capital structure, and
general economic and financial market conditions, including
fluctuations in currency exchange rates, economic instability, and
inflationary conditions (iii) the ability to implement business
plans, forecasts, and other expectations, and to identify and
realize additional opportunities, (iv) the risk that Science 37 may
never achieve or sustain profitability, (v) the risk that Science
37 will need to raise additional capital to execute its business
plan, which may not be available on acceptable terms or at all,
(vi) failure to realize anticipated cost savings, and (vii) risks
related to general economic and financial market conditions. The
foregoing list of factors is not exhaustive. You should carefully
consider the foregoing factors and the other risks and
uncertainties described in the “Risk Factors” section of Science
37’s Annual Report on Form 10-K for the fiscal year ended December
31, 2022, filed with the U.S. Securities and Exchange Commission
(the “SEC”) on March 6, 2023, and in the other documents filed by
Science 37 from time to time with the SEC. These filings identify
and address other important risks and uncertainties that could
cause actual events and results to differ materially from those
contained in the forward-looking statements. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and Science 37 assumes no obligation and does not intend to update
or revise these forward-looking statements, whether as a result of
new information, future events, or otherwise, except as required by
law. Science 37 does not give any assurance that Science 37 will
achieve its expectations.
MEDIA INQUIRIES:Grazia MohrenScience
37PR@science37.com
INVESTOR RELATIONS:Steve HalperLifeSci
AdvisorsInvestors@science37.com
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jul 2023 to Jul 2024